Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9PQ2N)

Drug Name

RO-23-7553 Drug Info

Synonyms

BXL-353; ILX-23-7553; (1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrovitamin D3

Indication

Disease Entry	ICD 11	Status	REF
Prostate disease	GA91	Phase 1	[1]

Cross-matching ID

PubChem CID: 6438384
CAS Number: CAS 118694-43-2
TTD Drug ID: DM9PQ2N

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vitamin D3 receptor (VDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[3]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[4]
Calcidiol	DMN4CV5	Hypophosphatemia		Approved	[3]
Doxercalciferol	DM6FG1P	Chronic kidney disease	GB61	Approved	[5]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[6]
Falecalcitrol	DMBI9ZJ	Hyperparathyroidism	5A51	Approved	[7]
Dihydrotachysterol	DMFB97P	Hypocalcemia	5B5K.1	Approved	[8]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[9]
Paricalcitol	DMYBV3G	Hyperparathyroidism	5A51	Approved	[10]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vitamin D3 receptor (VDR)	TTK59TV	VDR_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00004926) ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy. U.S. National Institutes of Health.
2	Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997 Aug;3(8):1331-8.
3	Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
4	Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
5	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
6	Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
7	Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
8	In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
9	[Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
10	New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
11	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.